AR074314A1 - Pirrolidinas, antagonistas de ep2 - Google Patents
Pirrolidinas, antagonistas de ep2Info
- Publication number
- AR074314A1 AR074314A1 ARP090104350A ARP090104350A AR074314A1 AR 074314 A1 AR074314 A1 AR 074314A1 AR P090104350 A ARP090104350 A AR P090104350A AR P090104350 A ARP090104350 A AR P090104350A AR 074314 A1 AR074314 A1 AR 074314A1
- Authority
- AR
- Argentina
- Prior art keywords
- optionally substituted
- independently
- aromatic rings
- alkyl
- alkyl optionally
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se refiere a una clase de compuestos de pirrolidina e fórmula (1), y sus derivados farmacéuticamente aceptables, a su uso en medicina, a composiciones que los contienen, y a procesos para su preparación. También se refiere a intermedios utilizados en la preparación de dichos compuestos y derivados. En particular, los compuestos de fórmula (1) son útiles para el tratamiento de trastornos mediados por EP2, como la endometriosis, los fibroides uterinos (leiomiomata), la menorragia, la adenomiosis, la dismenorrea primaria y secundaria (incluyendo los síntomas de dispareunia, disquexia y dolor pélvico crónico), el síndrome del dolor pélvico crónico, la enfermedad del rinón poliquístico. Reivindicación 1: Un compuesto caracterizado porque es de fórmula (1) en la que R1 es un grupo fenilo opcionalmente sustituido con uno o dos sustituyentes seleccionados cada uno independientemente de F, CI, Br, CN, alquilo C1-4, alquiltio C1-4, alcoxi C1-4, fluoroalquilo C1-4 y fluoroalcoxi C1-4, o es un grupo cicloalquilo C3-6; X representa un enlace directo, NH u O; Z se selecciona de ¬C(=O)O-R2, ¬C(=O)NH-SO2R3 y ¬CN, R2 es H o alquilo C1-6 opcionalmente sustituido con 1 a 3 átomos de flúor; R3 es alquilo C1-6 opcionalmente sustituido con 1 a 3 átomos de flúor; Ar es un grupo aromático que consiste en 1, 2 o 3 anillos aromáticos, en los que dichos anillos aromáticos se seleccionan cada uno independientemente de fenilo y un anillo heteroaromático de 5 o 6 miembros que contiene 1, 2, 3 o 4 heteroátomos seleccionados cada uno independientemente de N, O y S, y en los que dichos anillos aromáticos, si son 2 o más, pueden estar condensados y/o enlazados por uno o más enlaces covalentes, y en los que dichos anillos aromáticos están opcionalmente sustituidos con 1, 2 o 3 sustituyentes seleccionados cada uno independientemente de F, Cl, CN, OH, alquilo C1-6, alquiltio C1-6, fluoroalquilo C1-6, fluoroalquiltio C1-6, fluoroalcoxi C1-6, alcoxi C1-6, SO2R4, NR5R6, NHSO2R7, SO2NR8R9, CONR10R11 y NHCOR12; R4 y R7 son cada uno independientemente alquilo C1-6 opcionalmente sustituido con 1 a 3 átomos de F; R5, R6, R8, R9, R10, R11 y R12 son cada uno independientemente H o alquilo C1-6 opcionalmente sustituido con 1 a 3 átomos de flúor; o su sal farmacéuticamente aceptable, solvato (incluyendo hidrato) o profármaco.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11286908P | 2008-11-10 | 2008-11-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR074314A1 true AR074314A1 (es) | 2011-01-05 |
Family
ID=41503565
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090104350A AR074314A1 (es) | 2008-11-10 | 2009-11-10 | Pirrolidinas, antagonistas de ep2 |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US8278343B2 (es) |
| EP (1) | EP2364296A1 (es) |
| JP (1) | JP2012508225A (es) |
| KR (1) | KR20110083733A (es) |
| CN (1) | CN102209710A (es) |
| AP (1) | AP2011005728A0 (es) |
| AR (1) | AR074314A1 (es) |
| AU (1) | AU2009312427B2 (es) |
| BR (1) | BRPI0920924A2 (es) |
| CA (1) | CA2741589A1 (es) |
| CL (1) | CL2011001034A1 (es) |
| CO (1) | CO6382112A2 (es) |
| CR (1) | CR20110217A (es) |
| CU (1) | CU20110093A7 (es) |
| DO (1) | DOP2011000127A (es) |
| EA (1) | EA201100549A1 (es) |
| EC (1) | ECSP11011032A (es) |
| GE (1) | GEP20125607B (es) |
| IL (1) | IL212490A0 (es) |
| MA (1) | MA32782B1 (es) |
| MX (1) | MX2011004903A (es) |
| NI (1) | NI201100092A (es) |
| NZ (1) | NZ592311A (es) |
| PA (1) | PA8848001A1 (es) |
| PE (1) | PE20110663A1 (es) |
| SV (1) | SV2011003896A (es) |
| TN (1) | TN2011000211A1 (es) |
| TW (1) | TW201022234A (es) |
| UY (1) | UY32228A (es) |
| WO (1) | WO2010052625A1 (es) |
| ZA (1) | ZA201104310B (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201034675A (en) * | 2008-12-18 | 2010-10-01 | Sanofi Aventis | Method for treating macular degeneration |
| TW201326154A (zh) | 2011-11-28 | 2013-07-01 | 拜耳知識產權公司 | 作為ｅｐ２受體拮抗劑之新穎２ｈ－吲唑 |
| WO2013176220A1 (ja) * | 2012-05-25 | 2013-11-28 | 国立大学法人京都大学 | 概日リズム調整 |
| CN110041269A (zh) * | 2019-05-16 | 2019-07-23 | 海门瑞一医药科技有限公司 | 一种2-氯-5-羟基嘧啶的制备方法 |
| WO2022272062A1 (en) * | 2021-06-24 | 2022-12-29 | Reservoir Neuroscience, Inc. | Ep2 antagonist compounds |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5319099A (en) * | 1991-01-21 | 1994-06-07 | Shionogi Seiyaku Kabushiki Kaisha | 3-benzylidene-1-carbamoyl-2-pyrrolidone compounds useful as antiinflammatory agents |
| JP4554931B2 (ja) * | 2001-12-20 | 2010-09-29 | メルク セローノ ソシエテ アノニム | プロスタグランジン調節物質としてのピロリジン誘導体 |
| WO2007005176A1 (en) * | 2005-06-29 | 2007-01-11 | Allergan, Inc. | Pyrrolidinones for the treatment of glaucoma and ocular hypertension |
| US7592364B2 (en) * | 2006-02-28 | 2009-09-22 | Allergan, Inc. | Substituted gamma lactams as therapeutic agents |
| US7550448B2 (en) * | 2006-05-24 | 2009-06-23 | Allergan, Inc. | Therapeutic compounds |
| DE102006039912A1 (de) * | 2006-08-25 | 2008-03-20 | Bayer Healthcare Ag | Substituierte Spirotetronsäuren und ihre Verwendung |
| WO2008139287A1 (en) * | 2007-05-10 | 2008-11-20 | Pfizer Limited | Azetidine derivatives and their use as prostaglandin e2 antagonists |
-
2009
- 2009-10-30 CN CN2009801446055A patent/CN102209710A/zh active Pending
- 2009-10-30 GE GEAP200912219A patent/GEP20125607B/en unknown
- 2009-10-30 MX MX2011004903A patent/MX2011004903A/es active IP Right Grant
- 2009-10-30 EA EA201100549A patent/EA201100549A1/ru unknown
- 2009-10-30 EP EP09756838A patent/EP2364296A1/en not_active Withdrawn
- 2009-10-30 AP AP2011005728A patent/AP2011005728A0/xx unknown
- 2009-10-30 CA CA2741589A patent/CA2741589A1/en not_active Abandoned
- 2009-10-30 BR BRPI0920924A patent/BRPI0920924A2/pt not_active IP Right Cessation
- 2009-10-30 NZ NZ592311A patent/NZ592311A/xx not_active IP Right Cessation
- 2009-10-30 AU AU2009312427A patent/AU2009312427B2/en not_active Ceased
- 2009-10-30 KR KR1020117013231A patent/KR20110083733A/ko active IP Right Grant
- 2009-10-30 WO PCT/IB2009/054824 patent/WO2010052625A1/en active Application Filing
- 2009-10-30 PE PE2011001004A patent/PE20110663A1/es not_active Application Discontinuation
- 2009-10-30 JP JP2011535189A patent/JP2012508225A/ja not_active Ceased
- 2009-11-06 US US12/613,771 patent/US8278343B2/en not_active Expired - Fee Related
- 2009-11-09 TW TW098137955A patent/TW201022234A/zh unknown
- 2009-11-09 UY UY0001032228A patent/UY32228A/es not_active Application Discontinuation
- 2009-11-09 PA PA20098848001A patent/PA8848001A1/es unknown
- 2009-11-10 AR ARP090104350A patent/AR074314A1/es not_active Application Discontinuation
-
2011
- 2011-04-25 CU CU20110093A patent/CU20110093A7/es unknown
- 2011-04-26 CR CR20110217A patent/CR20110217A/es unknown
- 2011-04-26 IL IL212490A patent/IL212490A0/en unknown
- 2011-04-29 TN TN2011000211A patent/TN2011000211A1/fr unknown
- 2011-05-05 EC EC2011011032A patent/ECSP11011032A/es unknown
- 2011-05-06 SV SV2011003896A patent/SV2011003896A/es unknown
- 2011-05-06 DO DO2011000127A patent/DOP2011000127A/es unknown
- 2011-05-09 CL CL2011001034A patent/CL2011001034A1/es unknown
- 2011-05-09 NI NI201100092A patent/NI201100092A/es unknown
- 2011-05-10 MA MA33829A patent/MA32782B1/fr unknown
- 2011-05-11 CO CO11058068A patent/CO6382112A2/es not_active Application Discontinuation
- 2011-06-09 ZA ZA2011/04310A patent/ZA201104310B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US8278343B2 (en) | 2012-10-02 |
| CL2011001034A1 (es) | 2011-11-11 |
| CO6382112A2 (es) | 2012-02-15 |
| JP2012508225A (ja) | 2012-04-05 |
| GEP20125607B (en) | 2012-08-10 |
| CR20110217A (es) | 2011-05-12 |
| WO2010052625A1 (en) | 2010-05-14 |
| AU2009312427B2 (en) | 2011-10-20 |
| AP2011005728A0 (en) | 2011-06-30 |
| EA201100549A1 (ru) | 2011-12-30 |
| US20100120793A1 (en) | 2010-05-13 |
| SV2011003896A (es) | 2011-07-05 |
| AU2009312427A1 (en) | 2010-05-14 |
| EP2364296A1 (en) | 2011-09-14 |
| ECSP11011032A (es) | 2011-06-30 |
| TN2011000211A1 (fr) | 2012-12-17 |
| CA2741589A1 (en) | 2010-05-14 |
| IL212490A0 (en) | 2011-06-30 |
| TW201022234A (en) | 2010-06-16 |
| NI201100092A (es) | 2011-10-31 |
| UY32228A (es) | 2010-06-30 |
| MX2011004903A (es) | 2011-05-30 |
| PE20110663A1 (es) | 2011-09-23 |
| PA8848001A1 (es) | 2010-06-28 |
| MA32782B1 (fr) | 2011-11-01 |
| DOP2011000127A (es) | 2011-07-15 |
| BRPI0920924A2 (pt) | 2016-10-04 |
| CN102209710A (zh) | 2011-10-05 |
| NZ592311A (en) | 2012-12-21 |
| ZA201104310B (en) | 2012-02-29 |
| CU20110093A7 (es) | 2012-01-31 |
| KR20110083733A (ko) | 2011-07-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1121699T1 (el) | Ενωσεις τριαζινης ως αναστολεις κινασης ρ13 και mtor | |
| PE20220931A1 (es) | Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina | |
| PE20220597A1 (es) | Inhibidores de la autofagia de fenilaminopirimidina amida y metodos de uso de estos | |
| AR119698A2 (es) | Compuesto amida n-urea sustituida derivado de aminoácido | |
| EA201290260A1 (ru) | Бензимидазол-имидазольные производные | |
| AR086983A1 (es) | Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak | |
| AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
| AR063151A1 (es) | Inhibidores de metaloproteasas de matriz | |
| AR100442A1 (es) | Derivados de pirido[1,2-a]pirimidin-4-ona para tratar atrofia muscular espinal | |
| AR074814A1 (es) | Pirimidinas sustituidas como antagonistas del receptor ccr2 y usos de las mismas en medicamentos. | |
| AR089671A1 (es) | 1,4-dihidropirimidinas 4,4-disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b | |
| PE20070172A1 (es) | DERIVADOS BICICLICOS COMO INHIBIDORES DE p38 | |
| AR086546A1 (es) | Derivados de 7h-purin-8(9h)-ona como inhibidores de jak | |
| AR089143A1 (es) | Triazolopiridinas sustituidas con actividad inhibidora de ttk | |
| AR081426A1 (es) | Derivados de pirazol inhibidores del receptor sigma | |
| AR107042A1 (es) | Inhibidores de la tirosina quinasa de bruton y métodos de su uso | |
| AR067757A1 (es) | Derivados de imidazo[4,5-c]piridin-2-ona, composiciones farmaceuticas que los contienen, procedimiento para su preparacion y uso de los mismos como agentes antivirales. | |
| AR078638A1 (es) | Antagonistas del receptor de cgrp | |
| AR075583A1 (es) | Derivados de isoxazol/o-piridina con eslabon etilo o etenilo | |
| AR075975A1 (es) | Compuestos heterociclicos y su uso como inhibidores de la glucogeno sintetasa quinasa 3 | |
| AR074314A1 (es) | Pirrolidinas, antagonistas de ep2 | |
| CO6251201A2 (es) | Composiciones y metodos para el tratamiento de3 enfermedades y desordenes oftalmicos | |
| AR063906A1 (es) | Compuestos quimicos derivados del indazol, una composicion farmaceutica y procesos de prpeparacion de los compuestos | |
| AR087915A1 (es) | N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la bace1 | |
| EA201600403A1 (ru) | N-ацилиминогетероциклические соединения |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |